US EditionThere Is Only 1 GLP-1 Stock to Buy In 2025
8 Articles
8 Articles
There Is Only 1 GLP-1 Stock to Buy In 2025
Key Points in This Article: Ozempic’s introduction shifted obesity treatment from lifestyle to pharmacological solutions, using GLP-1 drugs to regulate appetite and glucose. GLP-1 drugs promote weight loss and diabetes control, with global sales hitting $40 billion in 2024 and projected to reach $100 billion by 2030. Despite multiple investment options in the GLP-1 market, only one stock stands out as the best buy for 2025. Nvidia made early…
Novo Nordisk, the company behind the drug Ozempic, among other things, has crashed on the stock market. At stake are not only thousands of billions of kronor of savers' money, but also the future of Denmark's economy and self-image. What went wrong? Andreas Cervenka investigates.
Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay
Novo Nordisk, the Danish maker of the wildly popular Ozempic and Wegovy drugs used for weight loss, was downgraded due to competition from compounding as well as arch rival Eli Lilly, a brokerage said on Tuesday. Article Attribution | Read More at Article Source The post Novo Nordisk is no longer a buy at UBS, which says compounding is here to stay appeared first on RocketNews.
13:24 Competition from its US rival Eli Lilly and cheap copycat versions is slowing growth at Danish pharmaceutical company Novo Nordisk, where the new CEO Mike Doustdar will focus on...
Danish pharmaceuticals suffer regulatory and legal pressures in the US as they reduce their rating and growth expectations
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
